Promis Neurosciences (PMN) vs Rani Therapeutics Holdings, Inc. (RANI)

Promis Neurosciences and Rani Therapeutics Holdings, Inc. are both Biotechnology companies. Promis Neurosciences and Rani Therapeutics Holdings, Inc. are of similar size ($107.3M and $103.8M). Promis Neurosciences grew revenue faster over the last twelve months: 450.0% against 78.7%. Promis Neurosciences has the higher net margin (0.00% vs −597.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Rani Therapeutics Holdings, Inc. leads on 8 and Promis Neurosciences on 7.

Valuation

Metric PMN RANI Biotechnology median
P/E n/m n/m 7.88
P/S 46,834.02 28.17 11.47
P/B 2.09 2.96 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 24,347.61 20.72 10.73
Earnings yield (112.60%) (35.53%) (28.84%)
Free cash flow yield (40.87%) (14.30%) (23.03%)

Profitability

Metric PMN RANI Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (652.78%) 0.00%
Net margin 0.00% (596.97%) 0.00%
Free cash flow margin 0.00% (402.83%) 0.00%
Return on equity (172.30%) (155.24%) (57.72%)
Return on assets (127.57%) (77.54%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PMN RANI Biotechnology median
Revenue growth (TTM) 450.00% 78.73% 5.64%
EPS growth (last fiscal year) (922.18%) 57.14% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PMN RANI Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.85 5.31 4.73
Net debt to EBITDA 0.15 1.33 0.96

Dividend

Metric PMN RANI Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric PMN RANI Biotechnology median
Market cap 103.76m 107.32m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack